Botulinum neurotoxin A in the treatment of muscle spasticity: A review of new advances in mechanism, therapeutic strategies, and precision therapy

Zhao Hongbo, Yang Shengbo

doi:10.13418/j.issn.1001-165x.2026.2.17

2026 , Vol. 44 >Issue 2: 234 - 238

DOI: https://doi.org/10.13418/j.issn.1001-165x.2026.2.17

Botulinum neurotoxin A in the treatment of muscle spasticity: A review of new advances in mechanism, therapeutic strategies, and precision therapy

Expand

Department of Human Anatomy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China

Received date: 2025-11-06

Online published: 2026-04-16

Fold

Abstract

Muscle spasticity, frequently occurring after stroke or spinal cord injury, severely compromises motor function and quality of life. Botulinum neurotoxin A, a targeted neuromuscular junction blocker, serves as a first line treatment for focal spasticity. Its classic mechanism involves cleaving synaptosomal-associated protein 25, thereby inhibiting acetylcholine release. Recent research has unveiled its multi-level central modulatory effects. BoNT-A exerts systemic therapeutic benefits by reducing muscle spindle sensitivity, restoring spinal inhibitory balance, disrupting the “pain-spasm cycle,” and driving functional reorganization in the cerebral cortex. Clinically, it has proven effective in significantly improving muscle tone, range of motion, and pain. Current treatment is advancing toward greater precision. The use of imaging and electrophysiological guidance has enhanced injection accuracy. Research on novel targets, such as the nerve entry point and Intramuscular nerve dense region, aims to achieve "enhanced efficacy with reduced dosage." Furthermore, multimodal approaches combining BoNT-A with rehabilitation or extracorporeal shockwave therapy demonstrate synergistic advantages. However, long-term safety profiles, particularly concerning muscle structure and immunogenicity, require continued scrutiny. Future directions should integrate artificial intelligence-based prediction models, novel BoNT formulations, and multimodal strategies to advance treatment toward a higher standard of personalization and functional restoration.

Key words： Botulinum neurotoxin A; ; ; Muscle spasticity; ; ; Neuromuscular junction; ; ; Mechanism; ; ; Precision Therapy

Cite this article

Zhao Hongbo, Yang Shengbo . Botulinum neurotoxin A in the treatment of muscle spasticity: A review of new advances in mechanism, therapeutic strategies, and precision therapy[J]. Chinese Journal of Clinical Anatomy, 2026 , 44(2) : 234 -238 . DOI: 10.13418/j.issn.1001-165x.2026.2.17

References

[1] Wissel J, Ri S. Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post-stroke spastic movement disorder: updated perspectives on best practice[J]. Expert Rev Neurother, 2022, 22(1): 27-42. DOI:10.1080/14737175.2021.2021072.
[2] Gupta AD, Baguley I, Estell J, et al. Statement of the Rehabilitation Medicine Society of Australia and New Zealand for the therapeutic use of botulinum toxin A in spasticity management[J]. Intern Med J, 2024, 54(1): 178-182. DOI:10.1111/imj.16300.
[3] Gracies JM, Esquenazi A, Brashear A, et al. Efficacy and safety of abobotulinumtoxin A in spastic lower limb: Randomized trial and extension[J]. Neurology, 2017, 89(22): 2245-2253. DOI:10.1212/WNL. 0000000000004687.
[4] Ibrahim H, Retailleau K, Hornby F, et al. A Novel Catalytically Inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling[J]. Toxins (Basel), 2024, 16(1): 30. DOI: 10.3390/toxins16010030.
[5] Dunant Y, Gisiger V. Ultrafast and Slow Cholinergic Transmission. Different Involvement of Acetylcholinesterase Molecular Forms[J]. Molecules, 2017, 22(8): 1300. DOI:10.3390/molecules22081300.
[6] Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology[J]. Pharmacol Rev, 2017, 69(2): 200-235. DOI:10.1124/pr.116.012658.
[7] Zhou K, Luo W, Liu T, et al. Neurotoxins Acting at Synaptic Sites: A Brief Review on Mechanisms and Clinical Applications[J]. Toxins (Basel), 2022, 15(1): 18. DOI:10.3390/toxins15010018.
[8] Weise D, Weise CM, Naumann M. Central Effects of Botulinum Neurotoxin-Evidence from Human Studies[J]. Toxins (Basel), 2019, 11(1): 21. DOI:10.3390/toxins11010021.
[9] Li S, Francisco GE, Rymer WZ. A new definition of poststroke spasticity and the interferenceof spasticity with motor recovery from acute to chronic stages[J]. Neurorehabil Neural Repair, 2021, 35(7): 601-610.
[10] Hok P, Veverka T, Hluštík P, et al. The Central Effects of Botulinum Toxin in Dystonia and Spasticity[J]. Toxins (Basel), 2021, 13(2): 155. DOI:10.3390/toxins13020155.
[11] Aslami ZV, Weitzner AS, Padovano W, et al. Evaluating mechanisms and surgical alternatives to hyperselective neurectomy for treatment of spasticity in a rat model of spinal cord injury[J]. Plast Reconstr Surg, 2025, 10: 1097. DOI:10.1097/PRS.0000000000012487.
[12] Simic J, Østlie K, Biering-Sørensen F, et al. The effect of short-term treatment with botulinum toxin a on muscle stiffness in stroke patients: an exploratory study[J]. J Rehabil Med, 2025, 57: jrm44318. DOI:10.2340/jrm.v57.44318.
[13] Costamagna D, Bastianini V, Corvelyn M, et al. Botulinum Toxin Treatment of Adult Muscle Stem Cells from Children with Cerebral Palsy and hiPSC-Derived Neuromuscular Junctions[J]. Cells, 2023, 12(16): 2072. DOI:10.3390/cells12162072.
[14]Poenaru D, Sandulescu MI, Cinteza D. Pain Modulation in Chronic Musculoskeletal Disorders: Botulinum Toxin, a Descriptive Analysis[J]. Biomedicines, 2023, 11(7): 1888. DOI:10.3390/biomedicines11071 888.
[15]Rasetti-Escargueil C, Palea S. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications[J]. Toxins (Basel), 2024, 16(6): 261. DOI:10.3390/toxins16060261.
[16]Vinehout K, Tynes K, Sotelo MR, et al. Changes in Cortical Activity in Stroke Survivors Undergoing Botulinum Neurotoxin Therapy for Treatment of Focal Spasticity[J]. Front Rehabil Sci, 2021, 2: 735819. DOI:10.3389/fresc.2021.735819.
[17]Veverka T, Hok P, Trnečková M, et al. Interhemispheric parietal cortex connectivity reflects improvement in post-stroke spasticity due to treatment with botulinum toxin-A[J]. J Neurol Sci, 2023, 446: 120588. DOI:10.1016/j.jns.2023.120588.
[18]Weise D, Weise CM, Naumann M. Central Effects of Botulinum Neurotoxin-Evidence from Human Studies[J]. Toxins (Basel), 2019, 11(1): 21. DOI:10.3390/toxins11010021.
[19] Cummins DD, Park HJ, Panov F. Neurosurgical treatment of spasticity: a potential return to the cerebellum[J]. Neurosurg Focus, 2024, 56(6): E3. DOI:10.3171/2024.3.FOCUS2446.
[20] Masakado Y, Abo M, Kondo K, et al. Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE)[J]. J Neurol, 2020, 267(7): 2029-2041. DOI:10.1007/s00415-020-09777-5.
[21] Intiso D, Simone V, Bartolo M, et al. High Dosage of Botulinum Toxin Type A in Adult Subjects with Spasticity Following Acquired Central Nervous System Damage: Where Are We at?[J]. Toxins (Basel), 2020, 12(5): 315. DOI:10.3390/toxins12050315.
[22]Yan Y, Fu X, Xie X, et al. Hip Adductor Intramuscular Nerve Distribution Pattern of Children: A Guide for BTX-A Treatment to Muscle Spasticity in Cerebral Palsy[J]. Front Neurol, 2019, 10: 616. DOI:10.3389/fneur.2019.00616.
[23]Ibrahim AA, Ollenschläger M, Klebe S, et al. Mobile digital gait analysis captures effects of botulinum toxin in hereditary spastic paraplegia[J]. Eur J Neurol, 2024, 31(8): e16367. DOI:10.1111/ene.163 67.
[24] Zorowitz RD, Jacinto J, Ashford S, et al. Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice[J]. J Rehabil Med, 2025, 57: jrm42605. DOI:10.2340/jrm.v57.42605.
[25]Gresits OZ, Vezér M, Engh MA, et al. Limited evidence of functional benefit after upper limb Botulinum Toxin treatment in children with cerebral palsy: systematic review and meta-analysis[J]. Am J Phys Med Rehabil, 2025, 104(2): 108-116. DOI:10.1097/PHM0000000000002533.
[26]Aygün Bilecik N, Tuna S, Karataş Ö, Balcı N. The impact of repeated applications of Botulinum Toxin A on the spasticity of the upper limb in stroke patient, Cohort study[J]. J Clin Med, 2025, 14(8): 2735. DOI:10.3390/jcm14082735.
[27]Rahman E, Carruthers JDA, Rao P, et al. Predictive Modeling of Immunogenicity to Botulinum Toxin A Treatments for Glabellar Lines[J]. Plast Reconstr Surg, 2025, 155(4): 676e-688e. DOI:10.1097/PRS.0000000000011748.
[28]Ellenbogen A, Hauser RA, Patel AT, et al. Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with Daxibotulinum toxin A[J]. Toxins (Basel), 2025, 17(3):133. DOI:10.3390/toxins17030133.
[29]Tsuchiya M, Morita A, Hara Y. Effect of Dual Therapy with Botulinum Toxin A Injection and Electromyography-controlled Functional Electrical Stimulation on Active Function in the Spastic Paretic Hand[J]. J Nippon Med Sch, 2016, 83(1): 15-23. DOI:10.1272/jnms.83.15.
[30]Déniz A, Saavedra P, Marrero I, et al. Effectiveness of Unfocused vs. Focal Shock Waves Combined with Botulinum Toxin on Spasticity in Brain-Damaged Patients[J]. Toxins (Basel), 2025, 17(5): 209. DOI: 10.3390/toxins17050209.
[31]Takeuchi K, Takebayashi T, Hanioka D, et al. Comparison of tendon and muscle belly vibratory stimulation in the treatment of post-stroke upper extremity spasticity: a retrospective observational pilot study[J]. Sci Rep, 2024,14(1): 4151. DOI:10.1038/s41598-024-54815-1.
[32]Jacinto J, Balbert A, Bensmail D, et al. Selecting Goals and Target Muscles for Botulinum Toxin A Injection Using the Goal Oriented Facilitated Approach to Spasticity Treatment (GO-FAST) Tool[J]. Toxins (Basel), 2023, 15(12): 676. DOI:10.3390/toxins15120676.
[33]周家宇, 杨胜波. 前臂前群肌痉挛神经阻滞靶点定位的研究进展[J]. 中国临床解剖学杂志, 2023, 41(4):496-498. DOI:10.13418/j.issn. 1001-165x.2023.4.23.
Zhou JY, Yang SB. Progress on the localization of nerve block target for anterior forearm muscles spasticity[J]. Chin J Clin Anat, 2023, 41(4): 496-498. DOI: 10.13418/j.issn.1001-165x.2023.4.23.
[34]Hauret I, Dobija L, Givron P, et al. Effectiveness of Ultrasound-guided VS Electrical-stimulation-guided Botulinum Toxin Injections in Triceps Surae Spasticity after Stroke: A Randomized Controlled Study[J]. J Rehabil Med, 2023, 55: jrm11963. DOI:10.2340/jrm.v55.11963.
[35]Graciani MT, Costa FHR, Rosso ALZ, et al. EMG versus US: a randomized clinical trial comparing the efficacy in guiding botulinum toxin treatment in cervical dystonia[J]. Arq Neuropsiquiatr, 2025, 83(6): 1-8. DOI:10.1055/s-0045-1809542.
[36]Albert AM, Magimairaj HP, Lakshmanan J, et al. Localizing motor entry points of adductor muscles of thigh for motor point procedures in the treatment of adductor spasticity[J]. Anat Cell Biol, 2024, 57(4): 503-510. DOI:10.5115/acb.24.065.
[37]Chen R, He L, He X, et al. Experimental study of the center of the intramuscular nerve dense region of the masseter muscle as the optimal botulinum neurotoxin A injection site[J]. Ann Anat, 2025, 261: 152697. DOI:10.1016/j.aanat.2025.152697.
[38]He X, Wen S, Liu X, et al. Optimal target localization for botulinum toxin A in treating splenius muscles dystonia based on the distribution of intramuscular nerves and spindles[J]. Anat Sci Int, 2025, 101(1): 44-53. DOI:10.1007/s12565-025-00831-8.
[39]Bavikatte G, Esquenazi A, Dimyan MA, et al. Safety and Real-World Dosing of OnabotulinumtoxinA for the Treatment of Adult Spasticity: Post Hoc Analysis of the Adult Spasticity International Registry Study[J]. Am J Phys Med Rehabil, 2024, 103(7): 580-587. DOI:10.1097/PHM.0000000000002410.
[40]Hwang IS, Ryu JW, Jin S, et al. Long-Term Enhancement of Botulinum Toxin Injections for Post-Stroke Spasticity by Use of Stretching Exercises-A Randomized Controlled Tria[J]l. Toxins (Basel), 2024, 16(6):267. DOI:10.3390/toxins16060267.
[41]Li HX, Xu K, Chen SL, et al. Current techniques for the treatment of spasticity and their effectiveness[J]. EFORT Open Rev, 2025, 10(5): 237-249. DOI:10.1530/EOR-2024-0156.
[42]Sagerfors M, Blaszczyk I, Chemnitz A, et al. Trends in spasticity-reducing surgery and botulinum toxin treatment for post-stroke spasticity: a register study on 6,258 patients in Sweden, 2010-2021[J]. J Rehabil Med, 2025, 57: jrm42684. DOI:10.2340/jrm.v57.42684.
[43]Leblong E, Piette P, Anne C, et al. Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity[J]. Toxins (Basel), 2025, 17(3): 103. DOI:10.3390/toxins17030103.
[44]Multani I, Manji J, Hastings-Ison T, et al. Botulinum Toxin in the Management of Children with Cerebral Palsy[J]. Paediatr Drugs. 2019, 21(4): 261-281. DOI:10.1007/s40272-019-00344-8.
[45]Li Z, Chong Y, Jin L, et al. Botulinum Toxin Treatment for Calf Contouring Based on the Study of Combined Injection of Gastrocnemius and Soleus[J]. Aesthet Surg J, 2024, 44(5): 545-555. DOI:10.1093/asj/sjad365.
[46]Krasavina DA, Ivanov DO, Orlova OR, et al. [Sequential use of botulinum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity][J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2025, 125(2): 80-85. DOI:10.17116/jnevro202512502180.
[47]Spina S, Facciorusso S, Cinone N, et al. Integrating Telemedicine in Botulinum Toxin Type-A Treatment for Spasticity Management: Perspectives and Challenges from Italian Healthcare Professionals[J]. Toxins (Basel), 2024, 16(12): 529. DOI:10.3390/toxins16120529.

Options

Outlines

模态框（Modal）标题

Abstract

Cite this article

References